GO-Y30 modulated TGF-β and Treg function, supressed STAT3 in breast and pancreatic cancer cells, and inhibited the PD-1 immune checkpoint to increase the efficacy of cancer immunotherapy (263–265, 267). Here, PDCD1 is linked to cancer.